Project title: CANNABINOID QUINONE SCAFFOLD FOR ANTINEOPLASTIC THERAPY

Company name : QUINOVA RX LTD.

TECHNOLOGICAL FIELD
Pharmaceuticals

KEY WORDS
Quinone, Antineoplastic
Drugs

PROJECT SUMMARY
QUINOVA RX LTD. is developing a novel cannabinoid quinone
scaffold for better and safer antineoplastic therapy.

Quinones of various chemical families serve as biological
modulators and are widely used as antineoplastic drugs.
Anthracyclines, daunorubicin and doxorubicin for example, are
used to treat several forms of cancer. Other quinones (mitomycin
C, streptonigrin, pirubicin and mitoxantrone) are also used as
anticancer drugs. Although these and other quinonoid compounds
are effective in the treatment of many different forms of cancer,
their side effects, the most severe being cumulative heart
toxicity, limit their use. The development of quinonoid compounds
that display antineoplastic and/or anti-angiogenic activity, but
are less toxic, is a major therapeutic goal.
Prof. Raphael Mechoulam from the Hebrew University in Jerusalem,
pioneer and awarded investigator in cannabinoids research,
developed a novel anticancer cannabinoid quinone scaffold of
compounds synthesized from cannabidiol, one of the most abundant
but not psychoactive cannabinoids of Cannabis sativa.
For example one of QUINOVA RX's compounds, HU-331 (cannabidiol
hydroxyquinone), demonstrated a significantly high
anti-proliferative effect against various human cancer cell lines
in vitro. HU-331 did not cause cancer cell cycle arrest, by
apoptosis or caspase activation, and was not mediated by reactive
oxygen species. It specifically inhibited DNA topoisomerase II.
In vivo, HU-331 was more active in inhibiting tumor xenografts in
nude mice then doxorubicin with much less cardiotoxic effect and
general toxicity profile.
QUINOVA RX has also found that HU-331 is strongly anti-angiogenic
both in-vitro, ex-vivo and in-vivo, by inducing apoptosis of
vascular endothelial cells.
Taken together, QUINOVA RX LTD. considers cannabinoid quinones,
to have high potential as a new anti-angiogenic and anticancer
chemotherapeutic drugs. Currently, the company is testing its
library of compounds for their efficacy to inhibit different kind
of cancers and further developing the first lead compound into
clinical trials.

ENTREPRENEURS
Dr. Pe'er David - CEO
Dr. Natalya Kogan - Founder
and CTO
Zvika Rubinstein - CEO of
the Meytav Technological Incubator - Chairman of the Board of
Directors
Dr. Ettie Pirak - VP
Technologies, Meytav Technological Incubator, Director

PROJECT STATUS
The company was established in May 2007.

Therapeutic use of quinonoid derivatives of cannabinoids
(WO-2005/067917, EP1706110).

COOPERATION REQUIRED
The company is seeking a partnership with a Pharmaceutical
company or a private equity investor in order to advance the drug
development process into clinical trials.
---------------------------------------------
TEL: 972-4-6818801 972-54-2494979 FAX: 972-4-6818806 EMAIL:
peer@meytavti.co.il

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about